论文部分内容阅读
目的 观察ABCG8 T400K基因多态性与阿托伐他汀降脂疗效的关系.方法 选取186例高脂血症病人(男、女各93例),口服阿托伐他汀(20 mg,qd)治疗4 wk,采用聚合酶链反应-限制性片断长度多态性(PCR-RFLP)的方法检测ABCG8 T400K基因多态性,测定治疗前后血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)水平.结果 ABCG8 T400K的变异频率为0.128;阿托伐他汀治疗后ABCG8 400K等位基因(TK+KK型)携带者HDL-C水平有升高的趋势,且经调整年龄、性别及治疗前血清TG、TC、LDL-C、HDL-C水平后,其HDL-C的变化率显著高于ABCG8400T纯合子(TT型)携带者((2.8±s 11.7)%VS(-0.9±8.4)%,P=0.014));而ABCG8 T400K基因多态性对阿托伐他汀治疗4 wk后TG、TC、LDL-C的变化率无明显影响.结论 ABCG8 T400K基因多态性可能影响阿托伐他汀改变高密度脂蛋白的疗效.“,”AIM To investigate the association between ABCG8 T400K polymorphism and the lipidlowering response to atorvastatin. METHODS Genotypes were determined using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) in 186 hyperlipidemic patients (male 93 and female 93) treated with atorvastatin 20 mg once daily for 4 weeks. Serum triglyceride (TG), total cholesterol (TC), lowdensity lipoprotein cholesterol (LDL-C) , and high density lipoprotein cholesterol (HDL-C) levels were determined before and after the treatment. RESULTS Variant allele frequency of ABCG8 T400K was 0.128. The level of HDL-C had an increasing tendency in subjects with the A BCG8 T400K variant allele, and the percentage change of HDL-C after the atorvastatin treatment was significantly increased than that in subjects with homozygous for the T allele ( (2.8± s 11.7) % vs (-0.9± 8.4) %, P = 0.014) ) after adjusted by age, gender, and TG, TC, LDL-C, and HDL-C levels of pretreatment. No significant association was found between ABCG8 T400K polymorphism and percentage change from baseline in TG, TC, and LDL-C levels.CONCLUSION ABCG8 T400K variation in the ABCG8 gene appears to affect the increasing response of HDL-C after the atorvastatin treatment.